The interview is available at www.wallstreetreporter.com directly via the following link: http://www.wallstreetreporter.com/2010/08/edap-nasdaq-edap-management-interview/ . About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit http://www.edap-tms.com, http://www.hifu-planet.com .
CONTACT:  EDAP TMS SA          Investor Relations / Legal Affairs          Blandine Confort          +33 4 72 15 31 72          bconfort@edap-tms.com          The Ruth Group          Investors:          Eric Schwerdtfeger           646-536-7026          eschwerd@theruthgroup.com